Care Property Invest reports results in line with our expectations. EPRA EPS came in at EUR 0.90 vs EUR 0.89 KBCSe. It increases its EPS guidance by +4.5% from EUR 1.11 to EUR 1.16 (1.13 KBCSe, delta 2.7%) which means the fourth quarter has to outperform our estimates, likely driven by lower overheads. This is the third guidance increase in a row as it started the year by guiding EUR 1.07. Part of this is explained by the € 0.96m one-off in 1Q25 related to the reversion of a remuneration provisi...
We increased our Target Price for Biotalys to € 7.5 (was €6.1) while maintaining our Buy rating after Biotalys announced that the US EPA (Environmental Protection Agency) has issued its proposed registration decision to approve its first biofungicide, Evoca. The EPA will now initiate the final phase in its regulatory review, allowing stakeholders such as growers and industry associations 15 days to provide feedback before finalizing its regulatory decision. The EPA has also posted a final rule e...
ONWARD Medical Publishes Closing of Bookbuild Offering NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR:...
Onward announced the placement of 11.3m new ordinary shares in a private placement by way of an accelerated bookbuild offering at an issue price of € 4.5 per share (approx. 12.5% discount to closing price prior to deal announcement) resulting in gross proceeds of € 50.85m. Onwards cash runway is extended through at least end of 2026 (previously 1H26), assuming no drawdown of the company's debt facility with Runway Growth. The transaction was supported by existing and new, long-only and sector sp...
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Successful transaction supported by strong demand from existing and new high-quality, lon...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.